A number of stocks fell in the afternoon session after the broader U.S. stock market declined amid investor caution and a pullback in technology stocks.
Aytu BioPharma (AYTU) delivered earnings and revenue surprises of -33.33% and +10.05%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?